Nexsen (ASX:NXN) commences FDA engagement as US regulatory pathway comes into focus
Nexsen has commenced formal engagement with the US Food and Drug Administration for its GBS Rapid Sensor, marking a defined
Nexsen has commenced formal engagement with the US Food and Drug Administration for its GBS Rapid Sensor, marking a defined
Nexsen Limited (ASX:NXN) strengthens its global clinical adoption potential with the strategic appointment of internationally recognised surgeon-scientist Professor Shekhar Kumta
Nexsen Limited (ASX:NXN) has begun clinical trials for its StrepSure® GBS Rapid Sensor, marking a pivotal step toward transforming real-time
Automated page speed optimizations for fast site performance